PB2-IN-2
PB2-IN-2 is an orally active PB2 inhibitor with RNA-dependent RNA Polymerase (RNP) IC50 = 0.2 nM, LRA (Ligand Receptor Assay) EC50 = 0.8 nM, Cytopathic Effect (CPE) EC50 = 0.1 nM. PB2-IN-2 exhibits broad-spectrum, nanomolar antiviral potency against a panel of influenza A strains (including H1N1pdm09, Lyon/1337/2007/H1N1, Tex12-Like/H3N2, PR/8/34/H1N1, WSN/1933/H1N1, rPR8(H1N1)/H7N9 with EC50 = 1.5, 3.6, 3.7, 13.8, 2.9 and 9.8 nM and all the CC50 values > 2 μM. PB2-IN-2 possesses an excellent pharmacokinetic profile and metabolic stability. PB2-IN-2 can be used for anti-influenza research.
For research use only. We do not sell to patients.
- Formula: C20H18F2N6O2
- Molecular Weight:412.39
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
PB2-IN-2 (compound 3) exhibits low lipophilicity (LogD 1.27)[1].
PB2-IN-2 has superior inhibitory activity against a range of wild-type and laboratory-adapted influenza A viruses (including H1N1pdm09, Lyon/1337/2007/H1N1, Tex12-Like/H3N2, PR/8/34/H1N1, WSN/1933/H1N1, rPR8(H1N1)/H7N9 with EC50= 1.5, 3.6, 3.7, 13.8, 2.9 and 9.8 nM and all the IC50 values > 2 μM) and good safety margin in A549 lung cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Parmacokinetics
| Species | Dose | Route | CL | Vss | T1/2 (Elimination) | F |
|---|---|---|---|---|---|---|
| Mice[1] | 2.0 mg/kg | i.v. | 9.2 mL/min/kg | 1.6 L/kg | 1.6 h | 62.4 % |
In Vivo
PB2-IN-2 (0.05-1 mg/kg, p.o., twice daily for 5 days) has low efficacious dose, shallow efficacy cliff and wide therapeutic window in the mouse influenza A virus infection model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:A/Puerto Rico/8/34 (3 × 105 TCID50, i.n.) induced-male BALB/c mice[1]
-
Dosage:0.05, 0.1, 0.3, and 1 mg/kg
-
Administration:p.o., twice daily for 5 days
-
Result:Provided 100% protection at a minimum dose of 0.3 mg/kg.
Achieved full protection maintaining in vitro EC50 coverage for more than 18 h.
Lost peak body weight at 10% by day 7 and recovered by day 14 at 0.3 mg/kg.
Chemical Information
-
Molecular Weight 412.39
-
Formula C20H18F2N6O2
-
SMILES
FC1=CN=C(N=C1N[C@H]2[C@@H]3CC[C@H]([C@@H]2C(O)=O)[C@@]4([H])[C@@]3(C4)[H])C5=NNC6=C5C=C(C=N6)F
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)